Not Too Late to Own ANI Pharmaceuticals (ANIP), Guggenheim Says

Guggenheim analyst Louise Chen reiterated a Buy rating and $79 price target on ANI Pharmaceuticals (NASDAQ: ANIP) following meetings with management.

Chen commented, "We remain positive on ANIP shares after hosting meetings with CEO, Art Przybyl, and CFO, Charlotte Arnold on 3/4/15. Although ANIP has outperformed (up +18% vs. S&P500 +2%) we would still be buyers because we continue to believe a large number of new approvals over the next 12 months should drive earnings growth to levels not reflected in consensus. Moreover, we expect more product acquisitions following ANIP’s recent $144MM convertible debt offering. Finally, we think ANIP's valuation is inexpensive. Companies with lower EBITDA forecasts for '15 have higher market caps than ANIP, like SGNT (NEUTRAL, $27.40) and IG (NC, $9.43)."

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $66.51 yesterday.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold